Reply to E. Hindié
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · Journal of Clinical Oncology · 2021
We thank Dr Hindié1 for her insightful comments and the pertinent question at the end of her deliberations. In our recent publication2 in the Journal of Clinical Oncology, we have demonstrated that the prolongation of recurrence-free survival (RFS) with pembrolizumab adjuvant therapy in the EORTC 1325/KEYNOTE-054 phase III trial, at a median follow-up of 3 years, is sustained and consistent in magnitude (hazard ratio [HR], 0.56) with the initially reported final analysis of this primary end point as published in 2018.3 In this trial, patients with melanoma were stratified as stage IIIA-B-C, according to the American Joint Committee on Cancer (AJCC)-7 staging system,4 with the specific prerequisite that stage IIIA patients must have a micrometastasis with a diameter > 1 mm according to the Rotterdam Criteria, to avoid a potentially large influx of patients with a very low risk of recurrence.
Cited by 2 works. doi:10.1200/jco.20.03463
Authors
- Alexander M.M. Eggermont
- Christian U. Blank
- Mario Mandalà
- Georgina Venetia Long
- Victoria G. Atkinson
- Stéphane Dalle
- Andrew Mark Haydon
- Andrey Meshcheryakov
- Adnan Khattak
- Matteo Salvatore Carlino
- Shahneen Kaur Sandhu
- James Larkin
- Susana Puig
- Paolo A. Ascierto
- Piotr Lukasz Rutkowski
- Dirk Schadendorf
- Rutger H.T. Koornstra
- Leonel Fernando Hernandez-Aya
- Anna Maria Di Giacomo
- Alfons J.M. van den Eertwegh
References
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
- Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma
- Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
- Adjuvant immunotherapy: the sting in the tail